UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 475

Sortiert nach

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

European journal of cancer (1990), 2017-10, Vol.84, p.212-218

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Journal of clinical oncology, 2006-01, Vol.24 (1), p.25-35

2006

Link zum Volltext

Verfügbarkeit prüfen

Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

Journal of clinical oncology, 2004-06, Vol.22 (12), p.2336-2347

2004

Link zum Volltext

Verfügbarkeit prüfen

Cutaneous side-effects of kinase inhibitors and blocking antibodies

The lancet oncology, 2005-07, Vol.6 (7), p.491-500

2005

Link zum Volltext

Verfügbarkeit prüfen

Patterns of progression in patients treated for immuno-oncology antibodies combination

Cancer Immunology, Immunotherapy, 2021-01, Vol.70 (1), p.221-232

2021

Link zum Volltext

Verfügbarkeit prüfen

Modern immunology is crucial to revealing the biological mechanisms of traditional Chinese medicine

Journal of Traditional Chinese Medical Sciences, 2023-10, Vol.10 (4), p.383-394

2023

Link zum Volltext

Verfügbarkeit prüfen

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

British journal of cancer, 2018-10, Vol.119 (8), p.937-939

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma

Clinical cancer research, 2007-03, Vol.13 (6), p.1801-1809

2007

Link zum Volltext

Verfügbarkeit prüfen

Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity

Pharmacology & therapeutics (Oxford), 2019-07, Vol.199, p.1-15

2019

Link zum Volltext

Verfügbarkeit prüfen

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib

Cancer research (Chicago, Ill.), 2007-07, Vol.67 (13), p.6253-6262

2007

Link zum Volltext

Verfügbarkeit prüfen

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors

Cell cycle (Georgetown, Tex.), 2011-03, Vol.10 (6), p.963-970

2011

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

European journal of cancer (1990), 2018-09, Vol.101, p.160-164

2018

Link zum Volltext

Verfügbarkeit prüfen

Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?

Annals of internal medicine, 2005-08, Vol.143 (4), p.313

2005

Link zum Volltext

Verfügbarkeit prüfen

Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs

European journal of cancer (1990), 2022-05, Vol.167, p.42-53

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Disease-Free Survivors in Metastatic Undifferentiated Carcinoma of Nasopharyngeal Type

Journal of clinical oncology, 2000-03, Vol.18 (6), p.1324-1330

2000

Link zum Volltext

Verfügbarkeit prüfen

Basic Fibroblast Growth Factor-2/β3 Integrin Expression Profile: Signature of Local Progression After Chemoradiotherapy for Patients With Locally Advanced Non–Small-Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2009-11, Vol.75 (3), p.696-702

2009

Link zum Volltext

Verfügbarkeit prüfen

Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction

Journal of clinical oncology, 2002-11, Vol.20 (21), p.4303-4312

2002

Link zum Volltext

Verfügbarkeit prüfen

Colchicine is an active treatment for everolimus-induced oral ulcers

European journal of cancer (1990), 2017-12, Vol.87, p.209-211

2017

Link zum Volltext

Verfügbarkeit prüfen

The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib

The oncologist (Dayton, Ohio), 2007-03, Vol.12 (3), p.281-290

2007

Link zum Volltext

Verfügbarkeit prüfen

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience

European journal of cancer (1990), 2018-07, Vol.98, p.17-22

2018

Link zum Volltext

Verfügbarkeit prüfen

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door

European journal of cancer (1990), 2018-03, Vol.92, p.1-10

2018

Link zum Volltext

Verfügbarkeit prüfen

Chimie et nouvelles thérapies

Jean-Pierre Armand, Marie-Priscille Brun, Janine Cossy, Joël Doré, Philippe Duchateau, Gérard Guillamot, Jean-François Haeuw, Patricia Melnyk, Alexandre Pachot, Sophie Postel-Vinay, Raphaël Rodriguez, Nathalie Strub-Wourgaft, Bruno Villoutreix, Bernard Meunier / Minh-Thu Dinh-Audouin, Danièle Olivier, Paul Rigny

2020

Link zum Volltext

Verfügbarkeit prüfen

Tyrosine kinase inhibition and grey hair

The Lancet (British edition), 2003-03, Vol.361 (9362), p.1056-1056

2003

Link zum Volltext

Verfügbarkeit prüfen

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

Investigational new drugs, 2005-06, Vol.23 (3), p.225-234

2005

Link zum Volltext

Verfügbarkeit prüfen

Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia

The cancer journal (Sudbury, Mass.), 2006-01, Vol.12 (1), p.47

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 475

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(406)
Mit Volltextzugriff
(437)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

Cutaneous side-effects of kinase inhibitors and blocking antibodies

Patterns of progression in patients treated for immuno-oncology antibodies combination

Modern immunology is crucial to revealing the biological mechanisms of traditional Chinese medicine

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma

Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?

Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs

Long-Term Disease-Free Survivors in Metastatic Undifferentiated Carcinoma of Nasopharyngeal Type

Basic Fibroblast Growth Factor-2/β3 Integrin Expression Profile: Signature of Local Progression After Chemoradiotherapy for Patients With Locally Advanced Non–Small-Cell Lung Cancer

Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction

Colchicine is an active treatment for everolimus-induced oral ulcers

The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door

Chimie et nouvelles thérapies

Tyrosine kinase inhibition and grey hair

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia

Suchergebnisse filtern